Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 10, 2022Frontiers in Cardiovascular MedicineOpen Access

Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy

View Full Paper
Ask AI
Bookmark
Share

Key result

Antitumor drugs including anthracyclines, immune checkpoint inhibitors, and trastuzumab are associated with significant cardiotoxicity, requiring continuous monitoring with biomarkers and imaging.

Why the study?

Antitumor drugs can cause significant cardiotoxicity that impairs prognosis and survival, necessitating an update on complications, monitoring strategies, and early detection methods.

Design

Review

Authors

WHWei HuangRXRong XuBZBin Zhou

Discussion

Loading...

Member takes

Overview

Reinforces surveillance needs in cardio-oncology patients; leaves optimal protocols and frequency open for prospective trials.

Structured PICO

P
Population
Patients with cancer receiving antitumor drugs (anthracyclines, immune checkpoint inhibitors, trastuzumab)

Continuous multimodal monitoring, including advanced imaging techniques like CMR and strain echocardiography, is crucial for the early detection and management of antitumor drug-induced cardiotoxicity.

Limitations

  • The specific mechanism of trastuzumab-related cardiotoxicity remains unclear.
  • The safe dose of anthracyclines remains unestablished.
  • The cost of cardiac magnetic resonance (CMR) is extremely expensive for population-based screening.

Cite This Study

Huang et al. (2022) conducted a review in Cardiotoxicity after antitumor strategy. Antitumor drugs (Anthracyclines, Immune Checkpoint Inhibitors, Trastuzumab) was evaluated. Antitumor drugs including anthracyclines, immune checkpoint inhibitors, and trastuzumab are associated with significant cardiotoxicity, requiring continuous monitoring with biomarkers and imaging.

synapsesocial.com/papers/6a2091f732c156e554b41d6ahttps://doi.org/10.3389/fcvm.2022.912329
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline2017 · 1,313 citations
  2. 2Congestive heart failure in patients treated with doxorubicin2003 · 2,331 citations
  3. 3ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.1992 · 324 citations
  4. 4Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol2016 · 696 citations
  5. 5Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children’s Oncology Group2019 · 40 citations